InventisBio (SH:688382) Xin Lang Zheng Quan·2025-09-30 03:18Core Viewpoint - Yifang Bio has shown significant stock price fluctuations and performance metrics, indicating both growth potential and recent challenges in the market [1][2]. Group 1: Stock Performance - As of September 30, Yifang Bio's stock price increased by 2.00% to 31.55 CNY per share, with a trading volume of 1.27 billion CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 18.247 billion CNY [1]. - Year-to-date, Yifang Bio's stock price has risen by 137.22%, but it has experienced a decline of 3.58% over the last five trading days and 22.80% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 11, where it recorded a net purchase of 68.8706 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yifang Bio reported a revenue of 19.1638 million CNY, reflecting a year-on-year growth of 28.85%, while the net profit attributable to shareholders was -119 million CNY, an increase of 44.25% compared to the previous period [2]. - As of June 30, 2025, the number of shareholders decreased by 7.28% to 9,790, while the average circulating shares per person increased by 7.85% to 40,990 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, notable institutional shareholders include Huatai-PineBridge Innovation Medicine Mixed A, which is the fourth largest shareholder with 9.9619 million shares, and Central Clearing Hong Kong Limited, which is a new shareholder with 8.0541 million shares [2]. - The fifth largest shareholder, China Europe Medical Health Mixed A, increased its holdings by 790,500 shares to 9.0924 million shares [2].